FDA WARNING_LETTER - Ideal Implant Incorporated - February 03, 2020
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
The FDA issued a Warning Letter to Dr. Hamas following an inspection of their Dallas, Texas facility from January 27 to February 3, 2020. The inspection revealed that the IDEAL IMPLANT Saline-Filled Breast Implant is an adulterated device under 21 U.S.C. § 351(h) due to non-conformity with Quality System (QS) regulation (21 CFR Part 820) and misbranded under 21 U.S.C. § 352(t)(2) for failing to furnish required information under 21 U.S.C. § 360i and 21 CFR Part 803.
Key violations include: 1. **Failure to maintain complaint files and procedures (21 CFR 820.198(a))**: The firm did not document complaint investigations and medical device reportability evaluations for complaints 19-0233 and 18-0095. The adequacy of the firm's responses was undetermined, as the revised "Complaint Files" procedure did not address "cancelled" complaints, and evidence of a retrospective review of all complaints was not provided. 2. **Failure to establish and maintain CAPA procedures (21 CFR 820.100(a))**: The firm failed to document corrective actions for sterilization load rejections
ID · fa3cc215-824c-40ab-8274-ee0402045279
Full citation text and observation details available on the Dashboard.